A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

NCT04940078 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity & Overweight

Interventions

DRUG: Cagrilintide
DRUG: semaglutide
DRUG: Cagrilintide and semaglutide

Sponsor

Novo Nordisk A/S